OPEN Research Article

Outcomes After Total Knee Arthroplasty in Patients With Autism: A Retrospective Database Study

Lucas Y. Kim, BS Katie M. Zehner, BS Scott J. Halperin, MD Jonathan N. Grauer, MD D

From the Department of Orthopaedics and Rehabilitation Yale School of Medicine, New Haven, CT.

Correspondence to Dr. Grauer: Jonathan. grauer@yale.edu

Dr. Grauer is editor-in-chief of North American Spine Society Journal and is on the board for North American Spine Society. None of the following authors or any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article: Mr. Kim, Ms. Zehner, and Dr. Halperin.

Mr. Kim and Ms. Zehner equal contribution.

JAAOS Glob Res Rev 2024;8: e24.00134

DOI: 10.5435/JAAOSGlobal-D-24-00134

Copyright 2024 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Orthopaedic Surgeons. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

ABSTRACT

Background: Autism spectrum disorder (ASD) is a

neurodevelopmental disorder associated with osteoarthritis for which total knee arthroplasty (TKA) may be considered. The safety and efficacy of TKA in patients with ASD had been poorly characterized. **Methods:** Total knee arthroplasty patients were identified using the M157 PearlDiver database. Patients with autism spectrum disorder were matched 1:4 with control TKA patients based on age, sex, and Elixhauser Comorbidity Index (ECI). 90-day adverse events were compared by multivariable regression, controlling for age, sex, and ECI. 5-year rates of revision were compared using Kaplan-Meier survival analyses.

Results: Of 1,194,063 TKA patients, ASD was identified in 352 (0.02%). Patients with autism spectrum disorder were younger (60.0 vs. 65.8 years, P < 0.001) with higher ECIs (7.8 vs. 4.2, P < 0.001) than control patients. Patients with autism spectrum disorder had higher odds of aggregated adverse events driven by sepsis (odds ratio [OR] 3.11), pneumonia (OR 3.55), and urinary tract infection (OR 3.02) (P < 0.0036 for each). 5-year revision rates were not significantly different for the matched cohorts (P = 0.8000).

Conclusion: Total knee arthroplasty patients with ASD had elevated odds of several infectious adverse events and may warrant additional perioperative precautions. No notable differences were observed in most adverse outcomes investigated, nor in 5-year implant survival, suggesting that patients with ASD can safely be considered for TKA.

utism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by repetitive behaviors and deficits in social interaction and communication.¹ In the United States, an estimated 2.2% of adults have ASD and the overall prevalence across age groups has been steadily increasing, from 1.1% in 2008 to 2.3% in 2018.^{2,3} As the prevalence of autism has increased, the population of older adults with the condition has increased, leading to an increased amount of recent research attention.⁴

It is notable that patients with ASD are at risk of many comorbidities and premature mortality.^{5–7} A crosssectional study of Medicare patients in 2016 to 2017 found that older adult patients with ASD had higher odds of health conditions that included osteoarthritis.⁸ While the specific reason for this greater risk is unknown, other studies have found that autistic traits were associated with a faster pace of aging and subsequently age-related conditions including osteoarthritis, osteoporosis, heart disease, and cancer.⁹

Total knee arthroplasty (TKA) is the definitive treatment of knee osteoarthritis refractory to other treatments.¹⁰ One epidemiological study found that the volume of TKA procedures in the United States increased by 156% between 2000 and 2019 and is projected to have a continued annual growth rate of over 4% by year.¹¹ With the increasing prevalence of diagnoses of ASD and the increased risk of osteoarthritis with age, more and more of those affected by ASD are expected to present as candidates for TKA.

Given the risk of multiple comorbidities and premature mortality in patients with ASD, it is important to understand condition-specific risks of undergoing TKA. However, there is a lack of knowledge surrounding surgical outcomes in patients with ASD. Thus, using a large, national database, this study evaluated postoperative outcomes among a cohort of patients with and without ASD undergoing TKA for osteoarthritis with the aim of understanding the postoperative adverse event profile and implant survival associated with ASD.

Methods

Database and Cohort

A retrospective study was conducted with data using the M157 PearlDiver Mariner Patient Claims Database (PearlDiver Technologies), a large national, administrative database containing over 157 million patients, from January 1, 2010, to October 31, 2021. The use of this database has been well established in total joint arthroplasty research.^{12–16} Because PearlDiver data are output in a deidentified/aggregated form, our institutional review board deemed studies using this database as exempt from review.

Adult patients undergoing primary TKA were identified based on Current Procedural Terminology code 27447. Exclusion criteria included age younger than 18 years; a lack of osteoarthritis diagnosis; a diagnosis of trauma, infection, or neoplasm within 90 days before surgery; and not being active in the database for at least 90 days after surgery.

Patients with ASD were identified with the International Classification of Diseases 9th and 10th revision (ICD-9 and ICD-10) codes ICD-9-D-29900 and ICD-10-D-F840 and matched with control patients 1:4 based on age, sex, and Elixhauser Comorbidity Index (ECI).¹¹

Postoperative Outcomes

The incidence of adverse events within 90 days of surgery was then abstracted from the database using ICD coding. Severe adverse events were defined as the occurrence of one of the following: cardiac events (myocardial infarction and cardiac arrest), sepsis, pulmonary embolism, surgical site infection, and deep vein thrombosis. Minor adverse events were defined as the occurrence of one of the following: pneumonia, urinary tract infection (UTI), acute kidney injury, wound complications (hematoma and wound dehiscence), and transfusion. The occurrence of any adverse event was defined as the occurrence of a severe or minor adverse event.

The incidence of hospital readmissions within 90 days was also abstracted from the database. 5-year revisions were identified based on Current Procedural Terminology codes 27134, 27137, and 27138.

Data Analyses

Differences in patient characteristics among the matched and unmatched control and ASD cohorts were determined in the univariable analysis through the Student *t*-tests and chi-square tests where appropriate. These tests were repeated after matching.

Multivariable regressions, controlling for age, sex, and ECI, were conducted to calculate odds ratios (ORs) and 95% confidence intervals for each of the 90-day postoperative complications.

Kaplan-Meier survival analyses were conducted for 5-year revision rates. Cumulative incidence at the end of 5 years was compared using log-rank tests.

All statistical analyses were conducted using Pearl-Diver software. Figures and tables were created using Microsoft PowerPoint (Microsoft Corporation) or GraphPad Prism version 9 (GraphPad Software). Significance was defined with a baseline of P < 0.05, with a Bonferroni correction applied to each set of analyses.

Results

Study Population

A total of 1,194,063 patients undergoing TKA for osteoarthritis were identified, who met the inclusion

criteria. Of this population, ASD was noted in 352 (0.03%). The ASD cohort was, on average, younger (60.0 vs. 65.8 years, P < 0.001) and had a higher ECI (7.8 vs. 4.2, P < 0.001). No notable difference was observed in gender distribution.

Matching the ASD to control cohorts 1:4 eliminated these demographic differences. The number of patients in the final study cohort was 1708. The number of control patients in this matched population was 1,365, and the number of patients with ASD was 343. Patient characteristics for the matched and unmatched cohorts are summarized in Table 1.

90-Day Outcomes

Overall, 90-day any adverse events were noted for 17.4% of the control cohort and 27.4% of the ASD cohort (P < 0.0001) (Table 2). Hospital readmissions within 90 days were found for 5.8% and 6.4% of the populations, respectively (not statistically significantly different).

Multivariable logistic regression analyses are summarized in Table 2 and Figure 1. On application of the Bonferroni correction, where P < 0.0036 was deemed significant, patients with ASD were found to have significantly increased odds of sepsis (OR 3.11), pneumonia (OR 3.55), and UTI (OR 3.02) and increased odds of the composite groups of minor adverse events (OR 2.16) and all adverse events (1.86).

5-Year Revisions

At 5 years postoperatively, Kaplan-Meier survival analysis found that in the ASD cohort, the proportion of patients without revision TKA was 95.1% while this proportion in the matched control cohort was 95.5%. A log-rank test showed this not to be statistically significantly different (P = 0.800, Figure 2).

Discussion

With increasing incidence of TKA and an aging ASD population,^{3,17} more patients with ASD will be considered for TKA. However, the complication profile of such patients relative to those without ASD has not previously been described in the literature.

Patients with ASD comprised a small proportion of the overall TKA cohort (0.03%). The unmatched ASD cohort was markedly younger and had a higher comorbidity burden than the control cohort. A recent cross-sectional study of Medicare patients found that osteoarthritis was more common in patients with ASD.⁸ The higher comorbidity burden is consistent with previous literature showing greater multiorgan comorbidities in patients with ASD.^{5–8}

Matched patients with ASD were at independently elevated odds of sepsis, pneumonia, and UTI relative to patients without ASD, also driving elevated overall odds of all or minor adverse events. There is a known association between ASD and immunological conditions, including allergic, inflammatory, and autoimmune conditions, and immune dysregulation including adverse reactions to benign factors such as common illness, vaccinations, and environmental challenges.^{18,19} Furthermore, previous literature has shown that adult patients with ASD are more likely to be discharged to skilled nursing facilities after hospital encounters for trauma.²⁰ Given the high incidence of nosocomial infection in skilled nursing facilities,²¹⁻²³ discharge location could also be contributing to elevated odds of infectious adverse events in patients with ASD.

Of note, no differences were found for the noninfectious medical complications or other infectious medical complications, including surgical site infection. It is further noted that 5-year survival to revision was not markedly different among patients with versus without ASD.

	Nonmatched TKA Groups			Matched TKA Groups (4:1)		
Factor or Variable	Nonautism	Autism	Р	Nonautism	Autism	P
Total	1,193,711	352		1365	343	
Age (mean \pm SD)	65.8 ± 8.7	60.0 ± 11.5	<0.001	60.6 ± 10.7	60.4 ± 10.79	0.804
Sex			0.176			1.000
Female	749,121 (62.8%)	204 (58.0%)		801 (58.7%)	201 (58.6%)	
Male	444,587 (37.2%)	148 (42.0%)		564 (41.3%)	142 (41.4%)	
ECI (mean ± SD)	4.3 ± 3.2	7.8 ± 4.1	<0.001	7.6 ± 3.9	7.6 ± 3.9	0.992

Table 1. Descriptive Characteristics of Adult Total Knee Arthroplasty Patients With and Without Autism

ECI, Elixhauser Comorbidity Index; SD, standard deviation; TKA, total knee arthroplasty

	Un	ivariable	Multivariable, Controlling for Age, Sex, and ECI		
Factor or Variable	No Autism (n = 1365)	Autism (n = 343)	Р	OR (95% Cl) (n = 1708)	Р
90-day outcomes					
All adverse events	237 (17.4%)	94 (27.4%)	<0.0001	1.86 (1.40-2.48)	<0.0001
Severe events	111 (8.1%)	41 (12.0%)	0.034	1.56 (1.06-2.29)	0.025
Cardiac events	11 (0.8%)	<11	1	3.97 (0.25-63.95)	0.331
Sepsis	19 (1.4%)	14 (4.1%)	0.0026	3.11 (1.53-6.34)	0.002
Pulmonary embolism	22 (1.6%)	<11	0.303	1.66 (0.75-3.64)	0.209
Surgical site infection	25 (1.8%)	<11	0.467	1.45 (0.67-3.13)	0.350
Deep vein thrombosis	44 (1.9%)	11 (3.2%)	1	1.00 (0.51-1.95)	0.992
Minor events	168 (12.3%)	77 (22.4%)	<0.0001	2.16 (1.58-2.95)	<0.0001
Pneumonia	19 (1.4%)	16 (4.7%)	0.0003	3.55 (1.79-7.02)	0.0002
Urinary tract infection	65 (4.8%)	44 (12.8%)	<0.0001	3.02 (2.01-4.54)	<0.0001
Acute kidney injury	52 (3.8%)	24 (7.0%)	0.0158	2.01 (1.19-3.40)	0.009
Wound complication	32 (2.3%)	11 (3.2%)	0.472	1.39 (0.69-2.81)	0.358
Transfusion	34 (2.5%)	<11	0.800	1.18 (0.57-2.41)	0.657
90-day readmissions	79 (5.8%)	22 (6.4%)	0.755	1.12 (0.68-1.83)	0.661

 Table 2.
 Univariable and Multivariable Comparisons of 90-Day Adverse Events After Total Knee Arthroplasty in

 Patients With and Without Autism

CI, confidence interval; ECI, Elixhauser Comorbidity Index; OR, odds ratio; TKA, total knee arthroplasty

Bonferroni correction applied: P < 0.0036 deemed significant and bolded.

Wound complication: hematoma and wound dehiscence.

Cardiac events: cardiac arrest and myocardial infarction.

Like all administrative database studies, this study is limited by the accuracy and completeness of administrative coding. Additional knee-specific measures were not able to be assessed. We were also not able to investigate discharge location to assess whether differences in recovery location affected rates of adverse events.

Figure 1



Forest plot of OR and 95% confidence interval for multivariable analysis of 90-day outcomes after TKA for patients with and without autism spectrum disorder. CI, confidence interval; OR, odds ratio; TKA, total knee arthroplasty





5-year Kaplan-Meier curve of implant survival until revision TKA for patients with and without autism spectrum disorder. TKA, total knee arthroplasty

Overall, these findings suggest that, with appropriate perioperative considerations and monitoring, patients with ASD may safely be considered for TKA. Several 90day infectious complications should be noted, and additional attention/preventive measures may be warranted. These findings should be helpful for surgical planning and patient/family counseling.

References

1. Lord C, Brugha TS, Charman T, et al: Autism spectrum disorder. *Nat Rev Dis Primers* 2020;6:5-23.

2. Hirota T, King BH: Autism spectrum disorder: A review. *JAMA* 2023;329: 157-168.

3. CDC: CDC Releases First Estimates of the Number of Adults Living With ASD, Centers for Disease Control and Prevention, 2020. https://www.cdc. gov/ncbddd/autism/features/adults-living-with-autism-spectrum-disorder.html. Accessed October 3, 2023.

4. Mason D, Stewart GR, Capp SJ, Happé F: Older age autism research: A rapidly growing field, but still a long way to go. *Autism Adulthood* 2022;4: 164-172.

5. Hirvikoski T, Mittendorfer-Rutz E, Boman M, Larsson H, Lichtenstein P, Bölte S: Premature mortality in autism spectrum disorder. *Br J Psychiatry* 2016;208:232-238.

6. Schendel DE, Overgaard M, Christensen J, et al: Association of psychiatric and neurologic comorbidity with mortality among persons with autism spectrum disorder in a Danish population. *JAMA Pediatr* 2016;170: 243-250.

7. Ward JH, Weir E, Allison C, Baron-Cohen S: Increased rates of chronic physical health conditions across all organ systems in autistic adolescents and adults. *Mol Autism* 2023;14:35.

8. Hand BN, Angell AM, Harris L, Carpenter LA: Prevalence of physical and mental health conditions in Medicare-enrolled, autistic older adults. *Autism* 2020;24:755-764.

9. Mason D, Ronald A, Ambler A, et al: Autistic traits are associated with faster pace of aging: Evidence from the Dunedin study at age 45. *Autism Res* 2021;14:1684-1694.

10. Steinhaus ME, Christ AB, Cross MB: Total knee arthroplasty for knee osteoarthritis: Support for a foregone conclusion? *HSS J* 2017;13:207-210.

11. Shichman I, Roof M, Askew N, et al: Projections and epidemiology of primary hip and knee arthroplasty in medicare patients to 2040-2060. *JB JS Open Access* 2023;8:e22.00112.

12. Day W, Jayaram RH, Rubin LE, Grauer JN: Total hip arthroplasty in patients who have Marfan syndrome: Adverse events and 5-year revision rates. *J Arthroplasty* 2024;39:S275-S278.

13. Halperin SJ, Dhodapkar MM, Radford ZJ, Li M, Rubin LE, Grauer JN: Total knee arthroplasty: Variables affecting 90-day overall reimbursement. *J Arthroplasty* 2023;38:2259-2263.

14. Rudisill KE, Ratnasamy PP, Joo PY, Rubin LE, Grauer JN: Magnetic resonance imaging in the year prior to total knee arthroplasty: A potential overutilization of healthcare resources. *J Am Acad Orthop Surg Glob Res Rev* 2023;7:e22.00262.

15. Jayaram RH, Gillinov SM, Caruana DL, et al: Total hip arthroplasty imageless navigation does not reduce 90-day adverse events or five-year revisions in a large national cohort. *J Arthroplasty* 2023;38:862-867.

16. Mercier MR, Moore HG, Wolfstadt JI, Rubin LE, Grauer JN: Outcomes following total hip arthroplasty in patients with postpolio syndrome: A matched cohort analysis. *J Arthroplasty* 2022;37:1822-1826.

17. Dietz PM, Rose CE, McArthur D, Maenner M: National and state estimates of adults with autism spectrum disorder. *J Autism Dev Disord* 2020;50:4258-4266.

18. Robinson-Agramonte MdLA, Noris García E, Fraga Guerra J, et al: Immune dysregulation in autism spectrum disorder: What do we know about it? *Int J Mol Sci* 2022;23:3033.

Efficacy of Total Knee Arthroplasty in Patients With Autism

19. Al-Beltagi M: Autism medical comorbidities. *World J Clin Pediatr* 2021; 10:15-28.

20. McLaughlin CJ, Childress P, Armen SB, Allen SR: Adult trauma patients with autism spectrum disorder: A case-control study to evaluate disparities after injury. *Injury* 2021;52:3327-3333.

21. Cassone M, Mody L: Colonization with multidrug-resistant organisms in nursing homes: Scope, importance, and management. *Curr Geriatr Rep* 2015;4:87-95.

22. Haley RW, Culver DH, White JW, Morgan WM, Emori TG: The nationwide nosocomial infection rate: A new need for vital statistics. *Am J Epidemiol* 1985;121:159-167.

23. The burden of infection in long-term care, IN *Infection Control & Hospital Epidemiology*. Cambridge Core. https://www.cambridge.org/ core/journals/infection-control-and-hospital-epidemiology/article/abs/ burden-of-infection-in-longterm-care/

A0649711EB96DE62339914C778127BEA. Accessed October 5, 2023.